Clinical and metabolic characteristics of treated hyperlipidemic patients additionally affected by subclinical hyperglycemia

Lipids in Health and Disease

Volumn 15, Issue 1, 2016, Pages

  Leutner, Michael ^a   Göbl, Christian ^b   Wielandner, Alice ^a   Howorka, Eleonora ^a   Prünner, Marlies ^a   Bozkurt, Latife ^a   Schlager, Oliver ^a   Charwat Resl, Silvia ^a   Kautzky Willer, Alexandra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

Author keywords

Dyslipidemia; Intima media thickness; Metabolic characteristics; Normal glucose regulation; Prediabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C;

ADULT; AGE; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HOMEOSTATIC MODEL ASSESSMENT OF INSULIN RESISTANCE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; STENOSIS; WAIST CIRCUMFERENCE; COMPLICATION; HYPERLIPIDEMIAS; METABOLISM; MIDDLE AGED;

AGE FACTORS; CAROTID INTIMA-MEDIA THICKNESS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; MALE; MIDDLE AGED;

EID: 84954162209     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/s12944-016-0180-0     Document Type: Article

References (38)

1. Sun P, Dwyer KM, Merz SN, Sun W, Johnson CA, Shircore AM, et al. Blood pressure, LDL cholesterol, and intima media thickness: a test of the "response to injury" hypothesis of atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2005-210.
2. Riccioni G, D'Orazio N, Palumbo N, Bucciarelli V, Ilio E, Bazzano LA, et al. Relationship between plasma antioxidant concentrations and carotid intima-media thickness: the Asymptomatic Carotid Atherosclerotic Disease in Manfredonia Study. Eur J Cardiovasc Prev Rehabil. 2009;16:351-7.
3. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 1996;3(2):213-9.
4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med. 1977;62(5):707-14.
5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486-97.
6. Ford ES, Zhao G, Li C. Pre-diabetes and the risk for cardiovascular disease: a systematic review of the evidence. J Am Coll Cardiol. 2010;55(13):1310-7.
7. Temelkova-Kurktschiev TS, Koehler C, Leonhardt W, Schaper F, Henkel E, Siegert G, et al. Increased intimal-media thickness in newly detected type 2 diabetes: risk factors. Diabetes Care. 1999;22(2):333-8.
8. Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012;55(1):88-93.
9. Khambalia A, Phongsavan P, Smith BJ, Keke K, Dan L, Fitzhardinge A, et al. Prevalence and risk factors of diabetes and impaired fasting glucose in Naura. BMC Public Health. 2011;11:719.
10. Fontbonne A, Eschwège E, Cambien F, Richard JL, Ducimetière P, Thibult N, et al. Hypertriglyceridemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study. Diabetologia. 1989; 32(5):300-4. Eur Heart J. 2011;32:1769-818.
11. Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;32(14):1769-818.
12. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 2012;35:S65-71.
13. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090-101.
14. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-9.
15. Katz A, Nambi SS, Mather K, Baron AD, Follmann DA, Sullivan G, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85:2402-10.
16. Friedewald W, Levy R, Fredrickson D. Estimation of the Concentration of Low-Density Lipoprotein Cholesterol in Plasma Without Use of the Preparative Ultracentrifuge. Clin Chem. 1972;18(6):499-502.
17. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing 2014, Vienna, Austria. URL http://www.R-project.org/.
18. Marini MA, Succurro E, Castaldo E, Cufone S, Arturi F, Sciacqua A, et al. Cardiometabolic risk profiles and carotid atherosclerosis in individuals with prediabetes identified by fasting glucose, postchallenge glucose, and hemoglobin A1c criteria. Diabetes Care. 2012;35:1144-9.
19. Braicu MD, Pritulescu C, Alexandru D, Mota M. The Assessment of Subclinic Atherosclerosis Objected through IMT in Normal and Dyslipidemic Patients with Various Degrees of Glucose Tolerance. Rom J Intern Med. 2009;47(3):257-65.
20. Zhao Y, Li X, Tang S. Retrospective analysis of the relationship between elevated plasma levels of TXNIP and carotid intima-media thickness in subjects with impaired glucose tolerance and early Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2015;109(2):372-7.
21. Faeh D, William J, Yerly P, Paccaud F, Bovet P. Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity. Cardiovasc Diabetol. 2007;6:32.
22. Niskanen L, Rauramaa R, Miettinen H, Haffner SM, Mercuri M, Uusitupa M. Carotid Artery Intima-Media Thickness in Elderly Patients with NIDDM and in nondiabetic subjects. Stroke. 1996;27:1986-92.
23. Temelkova-Kurktschiev T, Koehler C, Schaper F, Henkel E, Hahnefeld A, Fuecker K, et al. Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals. Diabetologia. 1998;41(6):706-12.
24. Kowall B, Ebert N, Then C, Thiery J, Koenig W, Meisinger C, et al. Associations between Blood Glucose and Carotid Intima-Media Thickness Disappear after Adjustment for Shared Risk Factors: The KORA F4 Study. PLoS One. 2012;7(12), e52590.
25. Rasmussen-Torvik LJ, Li M, Kao WH, Couper D, Boerwinkle E, Bielinski SJ, et al. Association of a fasting glucose genetic risk score with subclinical atherosclerosis: The atherosclerosis risk in communities (ARIC) study. Diabetes. 2011;60(1):331-5.
26. Salonen R, Salonen JT. Progression of carotid atherosclerosis and its determinants: a population-based ultrasonography study. Atherosclerosis. 1990;81(1):33-40.
27. Su TC, Chien KL, Jeng JS, Chen MF, Hsu HC, Torng PL, et al. Age- and gender-associated determinant of carotid intima-media thickness: a community-based study. J Atheroscler Thromb. 2012;19(9):872-80.
28. Mainous AG, Tanner RJ, Baker R, Zayas CE, Harle CA. Prevalence of prediabetes in England from 2003 to 2011: population-based, cross-sectional study. BMJ Open. 2014;4(6), e005002.
29. Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract. 2009;63:1308-13.
30. Fuentes F, Alcala-Diaz JF, Watts GF, Alonso R, Muniz O, Díaz-Díaz JL, et al. Statins do not increase the risk of developing type 2 diabetes in familial hypercholesterolemia: The SAFEHEART study. Int J Cardiol. 2015;201:79-84.
31. Andersson C, Lyass A, Larson MG, Robins SJ, Vasan RS. Low-density-lipoprotein cholesterol concentrations and risk of incident diabetes: epidemiological and genetic insight from the Framingham Heart Study. Diabetologia. 2015;58(12):2774-80.
32. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354(9179):617-21.
33. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007;115:459-67.
34. Yamazaki T, Nohara R, Daida H, Hata M, Kaku K, Kawamori R, et al. Intensive lipid-lowering therapy for slowing progression as well as inducing regression of atherosclerosis in Japanese patients: subanalysis of the JART study. Int Heart J. 2013;54(1):33-9.
35. Österreichische Diabetes Gesellschaft. Diabetes mellitus - Anleitungen für die Praxis. Überarbeitete und erweiterte Fassung 2012. Dezember 2012 [Access date: 08.11.2015]. URL: http://www.oedg.org/pdf/1302-OEDG-Leitlinien.pdf.
36. American Diabetes Association. Standards of Medical Care in Diabetes-2012. Diabetes Care. 2012;35(1):S11-63.
37. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28.
38. Phillips DI, Clark PM, Hales CN, Osmond C. Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med. 1994;11(3):286-92.